Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Pediatr ; 124(1): 125-8, 1994 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-8283361

RESUMEN

Misalignment of pulmonary veins with alveolar capillary dysplasia is recognized as a rare cause of persistent pulmonary hypertension of the neonate. Until now, misalignment of pulmonary veins was thought to be a random occurrence, but its appearance in siblings at our institution suggests that there may be a familial predisposition. There have been reports of variable expression and variable severity in this disease; our report describes this variability in family members.


Asunto(s)
Anomalías Múltiples/genética , Síndrome de Circulación Fetal Persistente/etiología , Alveolos Pulmonares/irrigación sanguínea , Venas Pulmonares/anomalías , Anomalías Múltiples/patología , Capilares/anomalías , Femenino , Humanos , Lactante , Recién Nacido , Pulmón/irrigación sanguínea , Pulmón/patología , Masculino , Síndrome de Circulación Fetal Persistente/genética , Síndrome de Circulación Fetal Persistente/patología , Fenotipo , Alveolos Pulmonares/patología
2.
Int J Radiat Oncol Biol Phys ; 19(1): 85-7, 1990 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-2380099

RESUMEN

The efficacy of 5-iodo-2-deoxyuridine (IUDR) as a radiosensitizer when administered by continuous infusion into the cerebral spinal fluid (CSF) of the lateral cerebral ventricle was evaluated in a 9L gliosarcoma rat brain tumor model. Stereotactic implantation of a 5 x 10(4) tumor cell suspension into the left caudate nucleus was carried out in four groups of 10 rats each. Control animals had a median survival of 16.9 days (range 16-21 days). IUDR, 8.4 mg over 7 days administered by continuous infusion into the left lateral ventricle produced a slight survival advantage (median survival 21.5 days, range 12-56). Irradiation of the entire brain, 8 Gy on days 4, 6 and 7 after tumor cell implantation also produced a slight improvement in survival (median 19.5 days, range 17-34). The combination of radiation and IUDR infusion into the CSF produced a marked survival advantage (median 30.5, range 22-54) compared to the control and single modality treatment groups. This is the first demonstration of the effectiveness of IUDR as a radiosensitizer when administered into the lateral cerebral ventricle in the treatment of an intraparenchymal brain tumor.


Asunto(s)
Neoplasias Encefálicas/tratamiento farmacológico , Glioma/tratamiento farmacológico , Idoxuridina/administración & dosificación , Fármacos Sensibilizantes a Radiaciones/administración & dosificación , Animales , Neoplasias Encefálicas/radioterapia , Muerte , Glioma/radioterapia , Idoxuridina/uso terapéutico , Inyecciones Intraventriculares , Masculino , Trasplante de Neoplasias , Fármacos Sensibilizantes a Radiaciones/uso terapéutico , Ratas , Ratas Endogámicas F344
3.
J Natl Cancer Inst ; 81(17): 1322-5, 1989 Sep 06.
Artículo en Inglés | MEDLINE | ID: mdl-2769785

RESUMEN

A rat brain tumor model (Fischer 344 rats) with the clinical and pathological features of dissemination via the cerebrospinal fluid (CSF) pathways was used to demonstrate the efficacy of 5-iodo-2-deoxyuridine (IUDR) as a radiosensitizer when it is administered directly into the CSF. Stereotaxic implantation of 9L gliosarcoma cells (5 X 10(5) into the CSF of the lateral cerebral ventricle resulted in widespread dissemination and median survival of 18.5 and 20 days (range, 10-22) in two experiments. A continuous 7-day infusion of IUDR into the CSF starting on the day of tumor implantation did not provide any beneficial effect. Irradiation of the cranial spinal axis with 800 rad on days 4, 6, and 7 after implantation achieved an increase in survival time that was modest but statistically significant. However, the combination of IUDR infusion and radiotherapy resulted in marked improvement in survival time and a 10% cure rate (two of 20 rats). This is the first demonstration in vivo that IUDR administered into the CSF can be a potent radiosensitizer.


Asunto(s)
Neoplasias del Ventrículo Cerebral/radioterapia , Glioma/radioterapia , Idoxuridina/administración & dosificación , Animales , Neoplasias del Ventrículo Cerebral/mortalidad , Glioma/mortalidad , Idoxuridina/uso terapéutico , Inyecciones Intraventriculares , Fármacos Sensibilizantes a Radiaciones/administración & dosificación , Fármacos Sensibilizantes a Radiaciones/uso terapéutico , Ratas , Ratas Endogámicas F344 , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA